Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.85

€1.85

1.090%
0.02
1.090%
-
 
06.02.23 / Frankfurt WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Cerenis Therapeutics Holding S.A. Stock

There is an upward development for Cerenis Therapeutics Holding S.A. compared to yesterday, with an increase of €0.020 (1.090%).

Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years

Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cerenis Therapeutics Holding S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cerenis Therapeutics Holding S.A. 1.090% 1.422% 4.864% -14.167% 10.095% 362.921% -4.236%
Genomic Vision S.A. 29.030% 31.868% -56.204% -92.941% -36.508% -97.598% -99.587%
Sensorion SA -0.860% 3.288% 0.729% -47.810% 6.966% -60.514% -
Hybrigenics S.A. 19.170% 10.017% 23.408% -47.698% 31.537% -41.161% -88.638%

News

ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury


ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the